SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Payments of Stock Issuance Costs
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Payments of Stock Issuance Costs of $15.75 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of stock issuance costs for the quarter ending 2026-03-31 was $15.75K, a 91.19% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $31.20K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of stock issuance costs for fiscal 2025 was $557.66K, a 136.59% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of stock issuance costs for fiscal 2024 was $235.71K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of stock issuance costs for fiscal 2022 was $1.43M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $15.75K 10-Q · filed 2026-09-24 | $15.75K derived: sum of 3 quarters · filed 2026-09-24 | $46.95K derived: sum of 4 quarters · filed 2026-09-24 |
| 2026-03-31 | $15.75K 10-Q · filed 2026-05-15 | $15.75K derived: sum of 2 quarters · filed 2026-05-15 | $46.95K derived: sum of 3 quarters · filed 2026-05-15 | $394.66K derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $31.20K derived: sum of 2 quarters · filed 2026-03-31 | $378.91K derived: sum of 3 quarters · filed 2026-09-24 | $557.66K 10-K · filed 2026-03-31 |
| 2025-09-30 | $31.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $378.91K derived: sum of 2 quarters · filed 2026-09-24 | $557.66K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $347.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $526.46K 10-Q · filed 2026-09-24 | ||
| 2025-03-31 | $178.75K 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $235.71K 10-K · filed 2026-03-31 | |||
| 2022-12-31 | $23.32K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.43M 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $1.41M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |